The main benefit of next-generation vaccines is that they can be settled based on sequence information alone. If the viral protein(s) important to provide protection from infection or disease, and thus for inclusion in a vaccine (that is, the vaccine antigen), is known the availability of coding sequences for this viral protein(s) serves to start vaccine development, rather than having to be contingent on the facility to culture the virus. This makes these platforms highly adaptable and speeds up vaccine development considerably.

Nucleic acid-based vaccines can consist of DNA or mRNA and can be adapted quickly when new viruses emerge, which is why these were among the very first COVID-19 vaccines to enter clinical trials. For more details: Visit this site